Logo

Inflammatix: João Fonseca

Apr 16, 2020

Inflammatix has appointed João Fonseca as chief technology officer to oversee its molecular assay development and engineering teams as the firm advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification.

Since 2006, Fonseca has served as founder, CEO, and chief scientific officer of Biosurfit, a Lisbon, Portugal-based company whose blood tests diagnose multiple conditions at the point of care. The company's tests are broadly available throughout Europe.

Prior to Biosurfit, Fonseca was a professor in physics and experimental physics at the Technical University of Lisbon and a researcher at the University of Lisbon. He also founded a non-profit organization that works with patients and researchers to advance novel cancer treatments and research.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.